BioSpace News Archive

MobileHelp® has joined with the National Safety Council (NSC) to promote fall prevention through safer environments at home and on the go.

New director bring extensive pharmaceutical and business development expertise.

Amorsa Therapeutics Inc., is pleased to announce the appointment of Jeffrey Wiesen to its Board of Directors.

The International Childhood Oncology Network (ICON) will host its inaugural meeting at the annual American Society of Clinical Oncology (ASCO) conference in Chicago.

Royal Philips announced that it will be providing Philips HeartStart Onsite automated external defibrillators (AEDs) to Vail and Beaver Creek Mountains to create a cardiac arrest response system in collaboration with Starting Hearts and medic assist.

Updated subgroup analysis in 34 heavily pretreated patients with HER2-low-expressing metastatic breast cancer demonstrated a 50.0 percent confirmed overall response rate and an 85.3 percent disease control rate with DS-8201

- First-in-human safety data presented from phase 1/2 study with U3-1402, an investigational and potential first-in-class HER3-targeting antibody drug conjugate (ADC), in patients with heavily pretreated HER3-positive metastatic breast cancer - Preliminary efficacy data demonstrated a 47 percent confirmed overall response rate and a 94 percent disease control rate with U3-1402

All existing investors including Prosperico Ventures and Mr. Yinglin Mark Xu, Xynomic Pharma’s founder and Chairman, participated in this round of financing.

KARL STORZ Endoscopy-America, Inc. is pleased to announce that it has been awarded a three-year multi-source contract for its Video Laryngoscopes by Vizient, Inc.

Boston Scientific announced key data that will be presented at Digestive Disease Week (DDW).